Lymphoma Hub | Quarter Four 2019 Update

The Lymphoma Hub continues to disseminate the latest clinical updates in lymphoma and chronic lymphocytic leukemia (CLL).

Guided by an international Steering Committee of world experts, the Lymphoma Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. With an ever-expanding social media presence, the Lymphoma Hub engages with the global community on all major social media networks, providing a finger on the pulse of everyday, real-world clinical practice.

Our mission is to provide up to date, practical, and clinical advice to community hematologists and oncologists, and ensure patients with lymphoma and CLL have access to the latest therapies available.

The Lymphoma Hub is designed to deliver upon an unmet need for targeted medical updates, to help treatment teams involved in lymphoma and CLL care make informed therapeutic decisions. The Lymphoma Hub continued with the educational themes showcasing content relating to hot topics in lymphoma and CLL, focusing this quarter on prognostic factors in lymphoma. Additionally, the hub featured the latest clinical and translational insights gathered attending the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, US and provided a virtual social media coverage during the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), Berlin, DE. The Lymphoma Hub also hosted an expert discussion about promising updates in lymphoma at ASH 2019 meeting.

The Lymphoma Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage, and expert opinions, delivered by Scientific Education Support (SES).

SES strives to build communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

The Lymphoma Hub would like to thank our platinum supporter Celgene, silver supporters AstraZeneca and Janssen Oncology, and bronze supporters Roche and Nordic Nanovector, as well as contributor level supporter Karyopharm Therapeutics, for their continued support. This quarter, the Lymphoma Hub is proud to announce, Gilead as a new silver level supporter of the Lymphoma Hub.

For further information on the Lymphoma Hub, please visit: For media enquiries, or to explore collaboration opportunities, please contact:

Press release distributed by Pressat on behalf of Scientific Education Support, on Friday 17 January, 2020. For more information subscribe and follow

Lymphoma CLL Cancer Hematology Medical & Pharmaceutical
Published By

Scientific Education Support
Visit Newsroom


No media attached. Please contact Scientific Education Support for more information.

Additional PR Formats

You just read:

Lymphoma Hub | Quarter Four 2019 Update